Margetuximab | Interleukin Related interleukin-related.com

Product Name :
Margetuximab

Search keywords :
Margetuximab

drugId :
null

Target Vo:
Receptor protein-tyrosine kinase erbB-2

Target Vo Short Name :
HER2

Moa_Name:
Anti-HER2

First Approval Country :
United States

First Approval Date Filter:
2020

Origin Company_Name :
Raven Biotechnologies Inc

Active Company_Name :
GC Biopharma Corp

Active Indication_Name:
Breast Neoplasms

In Active Indication_Name:
Urinary Bladder Neoplasms

Termination Status :

China Termination Status :

Highest Status:
Approved

China Highest Status:
Approved

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
Phospho-IRF3 (Ser386) Antibody
Caveolin-1 Antibody
ZO-1/TJP1 Antibody: ZO-1/TJP1 Antibody is an unconjugated, approximately 191 kDa, rabbit-derived, anti-ZO-1/TJP1 polyclonal antibody. ZO-1/TJP1 Antibody can be used for: WB, ELISA, IHC-P, IHC-F, Flow-Cyt, IF expriments in human, pig, and predicted: mouse, rat, chicken, dog, cow, rabbit, guinea pig background without labeling.

Author: Interleukin Related

Related Posts